
Chimeric HLA-A*02:01 (ma3) &B2M&LMP2 (CLGGLLTMV) Monomer Protein



Cat. No.	MHC-HM41	3
Description		
Source		Recombinant Chimeric HLA-A*02:01(mα3)&B2M&LMP2 (CLGGLLTMV) Monomer Protein is expressed from HEK293 with His tag and Avi tag at the C-Terminus.
Cource		lt contains Gly25-Thr206(Human HLA-A*02:01 α1&α2)&Asp207-Glu299(Mouse H-2Ld α3), lle21-Met119(B2M) and CLGGLLTMV peptide.
Accession	Ì	A0A140T913(Human HLA-A*02:01 α1&α2)&P01897(Mouse H-2Ld α3)&P61769(B2M)&CLGGLLTMV
Molecular Weight		The protein has a predicted MW of 50.3 kDa. Due to glycosylation, the protein migrates to 52-65 kDa based on Tris-Bis PAGE result.
Endotoxin		Less than 1EU per µg by the LAL method.
Purity		> 95% as determined by Tris-Bis PAGE
Fully		> 95% as determined by HPLC
Formulation and Storage		
Formulatio	on	Lyophilized from 0.22µm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Reconstitu	ution	Centrifuge the tube before opening. Reconstituting to a concentration more than 100 µg/ml is recommended. Dissolve the lyophilized protein in distilled water.
Storage		-20 to -80°C for 12 months as supplied from date of receipt80°C for 3-6 months after reconstitution.2-8°C for 2-7 days after reconstitution.Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Background		
		The immunoproteasome, having been linked to neurodegenerative diseases and hematological cancers, has been shown to play an important role in MHC class I antigen presentation. The development of molecular probes that selectively inhibit the major catalytic subunit, LMP2, of the immunoproteasome,LMP2-rich cancer cells compared to LMP2-deficient cancer cells are more sensitive to growth inhibition by the LMP2-specific inhibitor,

implicating an important role of LMP2 in regulating cell growth of malignant tumors that highly express LMP2.

Assay Data



Chimeric HLA-A*02:01 (ma3) &B2M&LMP2 (CLGGLLTMV) Monomer on Tris-Bis PAGE under reduced and non-reduced condition. The purity is greater than 95%.

Chimeric HLA-A*02:01 (ma3) &B2M&LMP2 (CLGGLLTMV) Monomer Protein

12

14 min

10

4

6

8

KAGTUS Cat. No. MHC-HM413 Assay Data mAU 140 120 100 The purity of Chimeric HLA-A*02:01 (m α 3) 80 &B2M&LMP2 (CLGGLLTMV) Monomer was greater than 95% as determined by SEC-HPLC. 60 40 20


Chimeric HLA-A*02:01 (ma3) &B2M&LMP2 (CLGGLLTMV) Monomer Protein

Cat. No. MHC-HM413

Assay Data

ELISA Data

Chimeric HLA-A*02:01(ma3)&B2M&LMP2 (CLGGLLTMV), His Tag ELISA 0.5µg Chimeric HLA-A*02:01(ma3)&B2M&LMP2 (CLGGLLTMV), His Tag Per Well



Immobilized Chimeric HLA-

A*02:01(m α 3)&B2M&LMP2 (CLGGLLTMV) Monomer, His Tag at 5µg/ml (100µl/well) on the plate. Dose response curve for Anti-HLA-A*02:01&B2M&LMP2 (CLGGLLTMV) Antibody, hFc Tag with the EC50 of 5.4ng/ml determined by ELISA.

KVCJUS

Log Anti-HLA-A*02:01&B2M&LMP2 Antibody, hFc Tag Conc.(µg/ml)